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Abstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum   creatinine 
and was introduced to facilitate allocation of orthotopic liver transplantation (LT). The   objective 
is to determine the impact of MELD and kidney function on all-cause mortality. Among LTs 
performed in a tertiary referral hospital between 1995 and 2009, 419 cases were studied. 
Cox proportional hazards models were constructed to estimate the hazard ratios (HR) and 
95%   confidence intervals (CI) for death. Over mean follow-ups of 8.4 and 3.1 years during the 
pre-MELD and MELD era, 57 and 63 deaths were observed, respectively. Those   transplanted 
during the MELD era had a higher likelihood of hepatorenal syndrome (8% vs 2%, P , 0.01), 
lower kidney function (median estimated glomerular filtration rate [eGFR] 77.8 vs 92.6 mL/
min/1.73 m2, P , 0.01), and more pretransplantation renal replacement therapy (RRT) (5% 
vs 1%; P , 0.01). All-cause mortality risk was similar in the MELD vs the pre-MELD era 
(HR: 0.98, 95% CI: 0.58–1.65). The risk of death, however, was nearly 3-fold greater (95% CI: 
1.14–6.60) among those   requiring   pre-transplant RRT. Similarly, eGFR , 60 mL/min/1.73 m2 
post-transplant was associated with a 2.5-fold higher mortality (95% CI: 1.48–4.11). The study 
suggests that MELD implementation had no impact on all-cause mortality post-LT. However, 
the need for pre-transplant RRT and post-transplant kidney dysfunction was associated with a 
more than 2-fold greater risk of subsequent death.
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Introduction
Orthotopic liver transplantation (LT) has emerged as the standard treatment of 
patients with end-stage liver disease. Since the first successful LT in 1967, more than 
100,000 have been performed in the US.1 LT offers a reasonable long-term survival 
benefit, with several centers reporting more than 60% 5-year survival rate after 
surgery.2–4
Due to an increase in the number of patients requiring LT and a relatively   stagnant 
cadaveric donor pool, the number of patients dying on the waiting list has been 
  growing.5 To maximize the utility of this scarce resource, the Model for End-Stage 
Liver Disease (MELD) score was introduced by the United Network for Organ Sharing 
(UNOS) on February 27, 2002 to facilitate donor liver allocation. The MELD score, 
calculated from the patient’s serum bilirubin, creatinine, and international normal-
ized ratio for prothrombin time (INR), is an objective measurement that predicts the 
short-term mortality of patients awaiting liver transplantation. It is not affected by 
“subjective” criteria such as hepatic encephalopathy or ascites.6–10 Upon its introduction, 
however, there was concern that this model may lead to worse outcomes following LT, International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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because serum creatinine, a strong negative predictor of 
short- and long-term post-transplantation survival, was one 
of the major determinants of a MELD score.11 We sought 
to determine whether implementation of MELD influenced 
all-cause mortality in the context of perioperative and long-
term kidney function among liver transplant individuals using 
survival analysis.
Methods
Study design and population
We conducted a retrospective cohort study using electronic 
medical records and the UNOS registry. We identified all 
individuals who underwent LT between May 16, 1995 and 
April 22, 2009 at a single tertiary hospital with an active 
liver transplantation program. Individuals who were younger 
than 18 years, who received multiple organs, who underwent 
status 1A transplantation, or who had no follow-up 3 months 
after transplantation were excluded (n = 199). Our analysis 
included 419 individuals. The study was approved by the 
Johns Hopkins School of Medicine Institutional Review 
Board.
Outcome
The primary outcome of interest for this study was all-cause 
mortality. Vital status was obtained through the National 
Death Index, electronic medical record, and UNOS registry. 
Mortality follow-up was completed through April 30, 2010. 
Time to death was assessed as time from the date of trans-
plantation to the date of death.
exposures
The pre-MELD era was defined as the study period before 
February 27, 2002 when the MELD allocation policy was 
implemented. The MELD era was defined as the study 
period on or after this date. During the pre-MELD and 
MELD era, 163 and 256 individuals, respectively, under-
went LT. Pre-transplant variables included demographic 
factors (age, race, and gender), etiology of liver disease, 
and comorbid   conditions (hepatitis C infection, diabetes 
mellitus, and hypertension). Inclusion of diabetes mellitus 
and   hypertension as pre-transplant conditions was based 
on their presence as documented during the thorough pre-
transplantation evaluation. The class of drugs used for initial 
immunosuppression post-LT and length of hospitalization 
were abstracted from electronic medical records.
Serum creatinine at 1 month before LT was considered 
as the baseline value. Longitudinal serum creatinine was 
assessed at 3, 6, 12, and 24 months. Serum creatinine   values 
were   carried forward if missing at the next time point.   Kidney 
  function was estimated at all of these time points using the 
chronic kidney disease-epidemiology equation which   estimates 
the glomerular filtration rate (eGFR) based upon age, gender, 
and race according to serum creatinine level. For each time 
point, eGFR was dichotomized into ,60 mL/min/1.73 m2 
and $60 mL/min/1.73 m2. Patients who underwent at least 
one session of dialysis during their   hospitalization while 
  awaiting LT were designated as   having had pre-transplant 
renal replacement therapy (RRT).   Individuals who required 
RRT immediately following LT were designated as having 
post-transplant RRT. Hepatorenal syndrome was defined 
based on clinical diagnosis made by the medical team at the 
time of a participant’s hospitalization.
The MELD score for all individuals who underwent LT 
in the MELD era was calculated on the day of   transplantation 
in accordance with the UNOS formula:12 MELD score = 3.78 
(in serum bilirubin [in mg/dL]) +9.57 (in serum   creatinine 
[in mg/dL]) +11.2 (in INR) +6.43. Serum   bilirubin,   creatinine, 
and INR values less than 1 were set to 1 to preclude negative 
values, and serum creatinine upper-limit values were set at 
4.0 if the patient underwent RRT twice within 1 week prior 
to LT. No adjustments were made for malignancy or others 
conditions.
Statistical analysis
Data were analyzed using Stata/MP (v 11.1; StataCorp 
LP, College Station, TX). Continuous variables were 
  compared using the t-test or rank-sum test according to their 
distribution. Chi-square test was used to compare   categorical 
variables.
Kaplan–Meier product limit estimator function was used 
to evaluate the time to death following transplant according 
to the era of LT. Estimates were compared using the log-rank 
test. Univariable and multivariable Cox proportional hazards 
models were constructed to estimate the hazard ratio (HR) 
and 95% confidence interval (CI) for all-cause mortality 
between persons who underwent LT during the MELD vs 
pre-MELD era. Participants were administratively censored 
on December 31, 2009.
Kidney function was evaluated as a time-varying, 
binary covariate. For face validity, age, gender, and race 
were included in the multivariable model regardless of 
their statistical significance in univariable analyses. The 
remaining covariates were considered for inclusion in 
the multivariable model based on their clinical relevance International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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and statistical   significance. All reported P values were 
two-sided.   Sensitivity analysis, in which observation 
time was   truncated to allow for similar follow-up dura-
tions between the pre-MELD and MELD era groups, was 
also performed. We also performed sensitivity analyses 
in which individuals with hepatorenal syndrome were 
excluded.
Results
The pre-MELD and MELD participants were followed 
on average for 8.4 and 3.1 years, respectively. Overall 
  mortality was 29% (57 deaths in pre-MELD era and 
63 deaths in MELD era during the follow-up). Table 1 
displays sociodemographic and clinical characteristics 
of patients according to the LT era. Median MELD score 
for those in MELD era was 19.5 (interquartile range: 
14.5–24.0). The most common indication for LT was 
end-stage liver disease attributed to hepatitis C infection. 
Individuals who were transplanted during the MELD 
era were more likely to have hepatocellular carcinoma 
(12% vs 2%, P = 0.02), and suffer from hepatorenal 
  syndrome (8% vs 2%, P , 0.01). In addition, partici-
pants who   underwent LT during the MELD era had sig-
nificantly lower levels of   kidney   function (median eGFR 
77.8 vs 92.6 mL/min/1.73 m2, respectively; P , 0.01), 
with a greater proportion requiring renal replacement 
therapy prior to transplantation (5% vs 1%; P , 0.01). 
The initial immunosuppressive regimens   varied between 
the two groups, with a greater proportion of individu-
als   transplanted during the MELD era   receiving myco-
phenolate mofetil (74% vs 26%; P , 0.01) and fewer 
of these receiving calcineurin inhibitors (89% vs 99%; 
P , 0.01).
All-cause mortality
Kaplan–Meier curves showed that patients transplanted dur-
ing the MELD era had survival rates similar to those trans-
planted in the pre-MELD era (P = 0.14; Figure 1). The risk 
of all-cause death associated with LT in the MELD vs the 
pre-MELD era was similar in the unadjusted and adjusted 
analyses (crude HR: 1.35, 95% CI: 0.91–2.00; adjusted 
HR: 0.98, 95% CI: 0.58–1.65; Table 2). However, receipt of 
pre-transplant RRT was associated with significantly greater 
risk for all-cause mortality (Figure 2). In adjusted analy-
ses, the risk of death was nearly 3-fold greater (95% CI: 
1.14–6.60) among individuals who required pre-transplant 
RRT. Similarly, the HR for death was 2.5-fold higher (95% 
CI: 1.48–4.11) among persons who had eGFR ,60 mL/
min/1.73 m2 post-transplant. These risk estimates were 
unchanged when follow-up time was truncated to allow 
similar follow-up times between the pre-MELD and MELD 
era groups. Adjusted models excluding individuals with 
hepatorenal syndrome yielded similar risk estimates, but 
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Figure 1 Kaplan–Meier survival estimates by MeLD era with 120 (28.6%) deaths 
observed. estimates similar in sensitivity analyses.
Table 1 clinical characteristics according to era of liver trans-
plantation
Clinical  
characteristics
Pre-MELD  
(n = 163)
MELD  
(n = 256)
P value
Age, median year (IQR) 52 (46–58) 53 (47–57) 0.41
Black, n (%) 33 (20) 53 (21) 0.35
Women, n (%) 56 (34) 81 (32) 0.32
Diabetes, n (%) 37 (23) 76 (31) 0.11
hypertension, n (%) 25 (16) 60 (24) 0.08
Indication of liver transplantation
  hepatitis c, n (%) 60 (37) 147 (57) ,0.01
  hepatitis B, n (%) 4 (2) 13 (5)
  Alcohol, n (%) 24 (15) 22 (9)
  Other, n (%) 76 (47) 70 (27)
hepatocellular  
carcinoma, n (%)
3 (2) 32 (12) ,0.01
hepatorenal  
syndrome, n (%)
4 (2) 21 (8) 0.02
Baseline serum creatinine,  
median mg/dL (IQR)
0.9 (0.7–1.3) 1 (0.7–1.4) 0.03
Baseline egFR, median  
mL/min|1.73 m2 (IQR)
92.6  
(59.3–111.2)
77.7  
(51.1–105.2)
0.01
Required pre-transplant  
RRT, n (%)
1 (1) 13 (5) ,0.01
Required post-transplant  
RRT, n (%)
8 (5) 13 (5) 0.57
Perioperative length  
of stay, median days (IQR)
20 (12–42) 16 (10–30) ,0.01
Immunosuppressive medications
  calcineurin inhibitor 157 (99) 220 (89) ,0.01
  Mycophenolate mofetil 41 (26) 163 (74) ,0.01
  Steroids 141 (89) 230 (94) 0.06
Abbreviations: IQR, interquartile range; eGFR, estimated glomerular filtration rate.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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the hazard of death associated with pre-transplant RRT no 
longer reached statistical significance (adjusted HR: 2.98, 
95% CI: 0.90–9.87).
Discussion
The risk of all-cause mortality remains high, but is similar 
between the MELD and pre-MELD era. The need for pre-
transplant RRT, and kidney dysfunction after transplantation, 
are associated with a more than 2-fold greater risk of death 
after LT.
Similar to our findings, Yoo and Thuluvath also found 
that the post-liver transplant survival was unaffected in 
patients in whom the MELD score was used for organ 
  prioritization. However, their follow-up was relatively short 
(,10 months).13 Although one may argue that comparable 
outcomes between the MELD and pre-MELD era could 
be explained by the high rate of hepatorenal syndrome in 
the MELD era, which is likely to improve upon LT, our find-
ings were not affected by excluding those patients from the 
analyses. While the MELD score attempts to capture the 
severity of liver disease among potential liver   transplant 
recipients, the majority of its components include parameters 
such as serum bilirubin and INR values, which normalize 
upon transplantation of a functional liver. Moreover, the 
initial purpose of the MELD score was to predict death 
shortly following transjugular intrahepatic portosystemic 
shunt14 and subsequently to prognosticate outcomes among 
individuals with end-stage liver disease.8 Conversely, many 
factors aside from the use of MELD scores such as advances 
in surgical techniques, immunosuppression, anti-viral 
therapy, and most importantly, severity of underlying illness, 
may have influenced outcomes. If MELD has resulted in the 
transplantation of sicker patients as widely acknowledged, 
then comparable mortality rates in sicker patients suggest 
better outcomes rather than equal outcomes. The study 
by Bencker et al documented that despite the significant 
increase in the calculated MELD score in the post-MELD 
era compared to the pre-MELD era, 1-year survival 
post-transplant was not different.15 Those results confirm 
that this model was not developed to evaluate outcomes 
after liver transplant but rather to capture the severity of 
liver disease.
Similar to prior studies, we observed a significant risk 
of death associated with pre-transplant RRT and kidney 
dysfunction post-LT. Nair and colleagues demonstrated 
that pre-transplant renal dysfunction was an independent 
predictor of 30-day and 2-year mortality after adjusting for 
the recipient’s age, sex, etiology of liver disease, diabetes 
status, body mass index, cold ischemic time, and UNOS 
status.11 In their study, a creatinine clearance of less than 
40 mL/min was associated with significantly lower short- 
and long-term graft and patient survival rates.11 Similarly, 
pre-operative renal dysfunction was also an independent 
predictor of both short- and long-term survival after LT in 
Table 2 cox proportional hazards models for all-cause mortality
Covariates Univariable Multivariable (n = 394)
HR (95% CI) P value HR (95% CI) P value
MeLD era 1.35 (0.91–2.00) 0.14 0.98 (0.58–1.65) 0.94
Female 0.92 (0.63–1.36) 0.70 1.03 (0.62–1.70) 0.91
Black 1.00 (0.74–1.33) 1.00 1.15 (0.81–1.65) 0.43
Age, per year older 1.00 (0.98–1.02) 0.89 0.99 (0.97–1.02) 0.68
Required RRT pre-transplant 2.46 (1.14–5.28) 0.02 2.75 (1.14–6.60) 0.02
hepatitis c seropositive 1.56 (1.09–2.24) 0.02 1.56 (0.96–2.54) 0.07
hypertension 0.97 (0.89–1.54) 0.90 1.27 (0.69–2.32) 0.44
Diabetes 0.89 (0.58–1.36) 0.59 0.57 (0.31–1.04) 0.07
Time-varying egFR status (,60 vs $60)* 2.17 (1.37–3.43) ,0.01 2.47 (1.48–4.11) ,0.01
Note: *In mL/min/1.73 m2. 
Abbreviations: eGFR, estimated glomerular filtration rate; MELD, Model for End-Stage Liver Disease; RRT, renal replacement therapy.
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a small number of patients with non-biliary cirrhosis and 
fulminant hepatic failure and cirrhosis.16–19
Few studies have evaluated the relationship between the 
need for RRT post-transplant and overall mortality. Afonso 
and colleagues analyzed data collected prospectively from 
152 consecutive LTs performed by the same team from 
March 2003 to November 2007.20 They observed that 
patients who developed severe renal failure post-LT (serum 
creatinine .3 mg/dL or needing RRT) had worse outcomes 
compared with other patients; 95.29% vs 69.69% and 86.95% 
vs 41.66% for early and 1-year survivals,   respectively 
(P , 0.001).20 However, follow-up was shorter and the study 
included fewer patients compared with our study. In addition, 
our study is important as it does highlight the association 
of both pre-transplant and post-transplant renal failure with 
overall mortality.
Our study has several limitations to consider. We did not 
calculate the MELD score and thus the clinical risk profile 
for participants transplanted in the pre-MELD era may have 
differed from those in the MELD era. We, however, adjusted 
for one of the main components in the MELD calculation, 
serum creatinine. We did not have sufficient comparative 
data on pretransplant and intraoperative factors such as 
donor characteristics, ischemia time, and intraoperative 
blood loss. These factors, however, are likely to impact the 
peri operative mortality rather than mortality beyond 90 days 
post-transplant. Finally, significant differences in immuno-
suppressive regimens existed between the pre-MELD and 
MELD eras for which we could not adjust due to collinearity. 
As the indication for use of mycophenolate mofetil vs other 
immunosuppressive drugs is unknown, its association with 
renal function and therefore mortality is unclear. Although 
mycophenolate mofetil is non-nephrotoxic, patients who 
had underlying kidney disease may have been channeled to 
this drug.
Despite early concerns that implementation of the 
MELD allocation policy would augment the risk for 
death among liver recipients, our study demonstrates that 
  individuals transplanted in the MELD era experience 
similar survival as those transplanted in the pre-MELD 
era. Pre-transplant RRT and kidney function impairment 
following LT appears to be significantly associated with 
increased risk of death. Our findings outline the   importance 
of   monitoring kidney function among LT recipients. 
  Further studies are needed to elucidate the mechanisms by 
which kidney disease may contribute to excess mortality 
in this patient population.
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